BackBiostar Pharmaceuticals Overview

Biostar Pharmaceuticals Receivables

Biostar Pharmaceuticals's receivables is $460K.

Get informed when a big investor buys or sells

+ Follow
Receivables
$461031.00
↓ 92.43% YoYΔ $-5.63M vs prior year quarter

Peer trimmed avg / median

Loading

Biostar Pharmaceuticals Receivables History

Loading

Biostar Pharmaceuticals vs. peers: Receivables Comparison

Loading

Biostar Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Biostar Pharmaceuticals (BSPM) FAQ

As of the most recent data (September 2017), BSPM shows a receivables of $460K. That compares with $6.1M in the prior-year period — down 92.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BSPM's receivables is now $460K (was $6.1M) — a 92.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Biostar Pharmaceuticals is outperforming or lagging.

Tracking BSPM's receivables over time shows whether Biostar Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $460K That compares with $6.1M in the prior-year period — down 92.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Biostar Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $460K) with ownership activity and broader fundamentals.